news
WHO report suggests African countries are not ready for COVID-19 vaccines
The WHO Regional Director for Africa urges governments to “ramp up readiness” as report suggests the region is not prepared for a COVID-19 vaccine roll-out.
List view / Grid view
Drug Supply Chain
news
COVAXX commits to deliver 140 million COVID-19 vaccine doses to emerging markets
The company suggests their experimental COVID-19 vaccine, UB-612, has the features and potential to disrupt the traditional vaccine distribution and supply status quo.
news
EC announces new Pharmaceutical Strategy for Europe
The strategy outlines actions to strengthen EU supply chains, encourage innovation and ensure medicines are affordable and sustainable.
news
US pharma initiates litigation challenging HHS and FDA action
PhRMA and other organisations have challenged action by the HHS and FDA that permits the importation of drugs from Canada without drug manufacturers’ oversight.
article
How can Software as a Service drive collaboration and success in pharma?
In this Q&A, Nick Pike, Chief Revenue Officer at Vizibl, outlines with EPR’s Hannah Balfour the benefits of Software as a Service (SaaS) for pharmaceutical companies and describes how its adoption can enable companies to achieve many goals faster; from collaborating on bringing new products to market to reaching their…
news
Pharma supply chain still highly vulnerable to COVID-19 pandemic, says research
Report reveals global pharma supply chain leaders are afraid of the vulnerabilities in the end-to-end supply chain as the COVID-19 pandemic continues.
news
GSK sets goals of net zero impact on environment by 2030
GSK will use 100 percent renewable electricity usage among other efforts in its plans to have a net zero impact on the climate by 2030.
article
How will Trump’s ‘Buy American’ executive order impact pharmaceutical supply chains?
On 6 August 2020, US President Donald Trump signed an executive order, dubbed ‘Buy American’, with the aim of increasing the production of essential medicines in the US for domestic use. Here, Victoria Rees discusses the order and what it means for drug manufacturers in the US and rest of…
news
Pharma urged to review anti-counterfeiting strategies ahead of no-deal Brexit
According to various associations, the UK could experience a high influx of counterfeit medicines if it leaves the EU without a deal.
article
Availability of critical medicines during pandemics
The impact of COVID-19 is wide-reaching with disruptions to supply chains likely to continue over the coming years. In this article, Dave Elder discusses the effect of the pandemic on the supply and demand of critical medicines and what this means for pharma supply chains.
article
Who will receive COVID-19 vaccines first?
EPR’s Hannah Balfour discusses some of the proposed COVID-19 vaccine distribution plans and how medicinal nationalism and supply deals could prevent “fair and equitable access” to COVID-19 vaccines.
news
EC signs a joint procurement contract for remdesivir
The European Commission (EC) has signed a joint procurement contract to ensure an uninterrupted supply of Veklury (remdesivir) for participating countries.
news
Failure to secure ‘bare minimum’ deal on medicines could put patients at risk, MPs told
1 October 2020 | By
UK politicians were warned that without a post-Brexit deal on medicines, short-term supply delays could be damaging to both public health and the economy.
news
UK and EU pharma call for medicines to be prioritised in Brexit trade talks
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
article
Post-Brexit product supply: which way next for pharma?
Cecilia Avram details the requirements for pharma companies post-Brexit and provides practical pointers on minimising the disruption to cross-border product availability as new rules come into force.
